Cancer communications (London, England)

Keyphrases

Publications

volume 44, number 6, 2024

Zhichao Tong, Yubo Zhao, Shiyu Bai, Benedikt Ebner, Lou Lienhard, Yuling Zhao, Ziqi Wang, Qi Pan, Pengyu Guo, Thilo Bracht, Barbara Sitek, Jürgen E Gschwend, Wanhai Xu, Roman Nawroth
The mechanism of resistance to CDK4/6 inhibition and novel combination therapy with RNR inhibition for chemo-resistant bladder cancer. Cancer communications (London, England) 44 (6) (2024)
Anna Gustafsson, Emma Jonasson, Anders Ståhlberg, Göran Landberg
Proteomics of cell-free breast cancer scaffolds identify clinically relevant imprinted proteins and cancer-progressing properties. Cancer communications (London, England) 44 (6) (2024)
Chunyan Lan, Huaiwu Lu, Lin Zhou, Kunlun Liao, Junxiu Liu, Zhiwen Xie, Haixi Liang, Guorong Zou, Ting Yang, Qin Xu, Xin Huang
Long-term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study. Cancer communications (London, England) 44 (6) (2024)

volume 44, number 7, 2024

Christoph Heuser
Interleukin-10 gives exhausted chimeric antigen receptor (CAR) T cells a second breath. Cancer communications (London, England) 44 (7) (2024)
Lingjun Xiao, Louqian Zhang, Ciliang Guo, Qilei Xin, Xiaosong Gu, Chunping Jiang, Junhua Wu
"Find Me" and "Eat Me" signals: tools to drive phagocytic processes for modulating antitumor immunity. Cancer communications (London, England) 44 (7) (2024)
Qiqi Qiao, Shunfeng Hu, Xin Wang
The regulatory roles and clinical significance of glycolysis in tumor. Cancer communications (London, England) 44 (7) (2024)
Wei Mu, Pengfei Gu, Huating Li, Jinjin Zhou, Yulun Jian, Weiping Jia, Yang Ge
Exposure of benzo[a]pyrene induces HCC exosome-circular RNA to activate lung fibroblasts and trigger organotropic metastasis. Cancer communications (London, England) 44 (7) (2024)
Haiyang Zhou, Jiahui Yin, Anqi Wang, Xiaomao Yin, Taojun Jin, Kai Xu, Lin Zhu, Jiexuan Wang, Wenqiang Wang, Wei Zhang, Xinxiang Li, Zhiqian Hu, Xinxing Li
Single-cell landscape of malignant ascites from patients with metastatic colorectal cancer. Cancer communications (London, England) 44 (7) (2024)
Jiayu Wang, Yunjiang Liu, Qingyuan Zhang, Wei Li, Jifeng Feng, Xiaojia Wang, Jianmin Fang, Yiqun Han, Binghe Xu
Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study. Cancer communications (London, England) 44 (7) (2024)
Yuze Wu, Ming Yi, Mengke Niu, Binghan Zhou, Qi Mei, Kongming Wu
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors. Cancer communications (London, England) 44 (7) (2024)
Qiqi Qiao, Shunfeng Hu, Xin Wang
The regulatory roles and clinical significance of glycolysis in tumor. Cancer communications (London, England) 44 (7) (2024)
Jiayu Wang, Yunjiang Liu, Qingyuan Zhang, Wei Li, Jifeng Feng, Xiaojia Wang, Jianmin Fang, Yiqun Han, Binghe Xu
Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study. Cancer communications (London, England) 44 (7) (2024)
Christoph Heuser
Interleukin-10 gives exhausted chimeric antigen receptor (CAR) T cells a second breath. Cancer communications (London, England) 44 (7) (2024)
Christoph Heuser
Interleukin-10 gives exhausted chimeric antigen receptor (CAR) T cells a second breath. Cancer communications (London, England) 44 (7) (2024)
Lingjun Xiao, Louqian Zhang, Ciliang Guo, Qilei Xin, Xiaosong Gu, Chunping Jiang, Junhua Wu
"Find Me" and "Eat Me" signals: tools to drive phagocytic processes for modulating antitumor immunity. Cancer communications (London, England) 44 (7) (2024)
Jiayu Wang, Yunjiang Liu, Qingyuan Zhang, Wei Li, Jifeng Feng, Xiaojia Wang, Jianmin Fang, Yiqun Han, Binghe Xu
Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study. Cancer communications (London, England) 44 (7) (2024)
Yuze Wu, Ming Yi, Mengke Niu, Binghan Zhou, Qi Mei, Kongming Wu
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors. Cancer communications (London, England) 44 (7) (2024)
Wei Mu, Pengfei Gu, Huating Li, Jinjin Zhou, Yulun Jian, Weiping Jia, Yang Ge
Exposure of benzo[a]pyrene induces HCC exosome-circular RNA to activate lung fibroblasts and trigger organotropic metastasis. Cancer communications (London, England) 44 (7) (2024)
Qiqi Qiao, Shunfeng Hu, Xin Wang
The regulatory roles and clinical significance of glycolysis in tumor. Cancer communications (London, England) 44 (7) (2024)
Lingjun Xiao, Louqian Zhang, Ciliang Guo, Qilei Xin, Xiaosong Gu, Chunping Jiang, Junhua Wu
"Find Me" and "Eat Me" signals: tools to drive phagocytic processes for modulating antitumor immunity. Cancer communications (London, England) 44 (7) (2024)
Qiqi Qiao, Shunfeng Hu, Xin Wang
The regulatory roles and clinical significance of glycolysis in tumor. Cancer communications (London, England) 44 (7) (2024)
Christoph Heuser
Interleukin-10 gives exhausted chimeric antigen receptor (CAR) T cells a second breath. Cancer communications (London, England) 44 (7) (2024)
Haiyang Zhou, Jiahui Yin, Anqi Wang, Xiaomao Yin, Taojun Jin, Kai Xu, Lin Zhu, Jiexuan Wang, Wenqiang Wang, Wei Zhang, Xinxiang Li, Zhiqian Hu, Xinxing Li
Single-cell landscape of malignant ascites from patients with metastatic colorectal cancer. Cancer communications (London, England) 44 (7) (2024)
Wei Mu, Pengfei Gu, Huating Li, Jinjin Zhou, Yulun Jian, Weiping Jia, Yang Ge
Exposure of benzo[a]pyrene induces HCC exosome-circular RNA to activate lung fibroblasts and trigger organotropic metastasis. Cancer communications (London, England) 44 (7) (2024)
Yuze Wu, Ming Yi, Mengke Niu, Binghan Zhou, Qi Mei, Kongming Wu
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors. Cancer communications (London, England) 44 (7) (2024)

volume 44, number 8, 2024

Rolf F Barth, Gong Wu, Maria da Graca H Vicente, John C Grecula, Nilendu Gupta
Boron neutron capture therapy of cancer: where do we stand now? Cancer communications (London, England) 44 (8) (2024)
Sung Hee Choi, Jay Thomas Myers, Suzanne Louise Tomchuck, Melissa Bonner, Saada Eid, Daniel Tyler Kingsley, Kristen Ashley VanHeyst, Seong-Jin Kim, Byung-Gyu Kim, Alex Yee-Chen Huang
Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity. Cancer communications (London, England) 44 (8) (2024)
Sung Hee Choi, Jay Thomas Myers, Suzanne Louise Tomchuck, Melissa Bonner, Saada Eid, Daniel Tyler Kingsley, Kristen Ashley VanHeyst, Seong-Jin Kim, Byung-Gyu Kim, Alex Yee-Chen Huang
Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity. Cancer communications (London, England) 44 (8) (2024)
Sung Hee Choi, Jay Thomas Myers, Suzanne Louise Tomchuck, Melissa Bonner, Saada Eid, Daniel Tyler Kingsley, Kristen Ashley VanHeyst, Seong-Jin Kim, Byung-Gyu Kim, Alex Yee-Chen Huang
Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity. Cancer communications (London, England) 44 (8) (2024)
Jian Xiao, Shuqing Cao, Jiawei Wang, Pengyu Li, Quan Cheng, Xinyi Zhou, Jiacheng Dong, Yuan Li, Xinyu Zhao, Zekuan Xu, Li Yang
Leptin-mediated suppression of lipoprotein lipase cleavage enhances lipid uptake and facilitates lymph node metastasis in gastric cancer. Cancer communications (London, England) 44 (8) (2024)
Michael Schnekenburger, Anne Lorant, Sruthi Reddy Gajulapalli, Ridhika Rajora, Jin-Young Lee, Aloran Mazumder, Haeun Yang, Christo Christov, Hyoung Jin Kang, Bernard Pirotte, Marc F Diederich
Dual inhibition of sirtuins 1 and 2: reprogramming metabolic energy dynamics in chronic myeloid leukemia as an immunogenic anticancer strategy. Cancer communications (London, England) 44 (8) (2024)
Sangyeop Hyun, Youngmin Han, Jae Yun Moon, Young-Ah Suh, Won-Gun Yun, Wooil Kwon, Jong-Eun Lee, Daeun Kim, Ja-Lok Ku, Jin-Young Jang, Deachan Park
Defining and tracing subtypes of patient-derived xenograft models in pancreatic ductal adenocarcinoma. Cancer communications (London, England) 44 (8) (2024)
Sangyeop Hyun, Youngmin Han, Jae Yun Moon, Young-Ah Suh, Won-Gun Yun, Wooil Kwon, Jong-Eun Lee, Daeun Kim, Ja-Lok Ku, Jin-Young Jang, Deachan Park
Defining and tracing subtypes of patient-derived xenograft models in pancreatic ductal adenocarcinoma. Cancer communications (London, England) 44 (8) (2024)
Sung Hee Choi, Jay Thomas Myers, Suzanne Louise Tomchuck, Melissa Bonner, Saada Eid, Daniel Tyler Kingsley, Kristen Ashley VanHeyst, Seong-Jin Kim, Byung-Gyu Kim, Alex Yee-Chen Huang
Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity. Cancer communications (London, England) 44 (8) (2024)
Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan, Weibo Wang, Jun Liang, Xianwen Zhang, Feng Ye, Ping Chen, Huaizhang Wang, Zhenyan Yu, Lu Yue, Yong Fang, Jianping Xiong, Jianwei Yang, Yiye Wan, Xianli Yin, Wenling Wang, Nong Xu, Xiaohong Wang, Zemin Xiao, Huafang Su, Ying Wang, Kangsheng Gu, Shuiping Tu, Zishu Wang, Bo Liu, Xiaohua Hu, Weixian Liu, Xiaofeng Li
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study. Cancer communications (London, England) 44 (8) (2024)
Anjali Chander, Jacopo Iacovacci, Aize Pellon, Rhadika Kataria, Anita Grigoriadis, John Maher, Cynthia Sears, Gilad Bachrach, Teresa Guerrero Urbano, Mary Lei, Imran Petkar, Anthony Kong, Tony Ng, Ester Orlandi, Nicola Alessandro Iacovelli, Loris De Cecco, Mara Serena Serafini, David Moyes, Tiziana Rancati, Miguel Reis Ferreira
Fusobacterium is toxic for head and neck squamous cell carcinoma and its presence may determine a better prognosis. Cancer communications (London, England) 44 (8) (2024)
Rolf F Barth, Gong Wu, Maria da Graca H Vicente, John C Grecula, Nilendu Gupta
Boron neutron capture therapy of cancer: where do we stand now? Cancer communications (London, England) 44 (8) (2024)
Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan, Weibo Wang, Jun Liang, Xianwen Zhang, Feng Ye, Ping Chen, Huaizhang Wang, Zhenyan Yu, Lu Yue, Yong Fang, Jianping Xiong, Jianwei Yang, Yiye Wan, Xianli Yin, Wenling Wang, Nong Xu, Xiaohong Wang, Zemin Xiao, Huafang Su, Ying Wang, Kangsheng Gu, Shuiping Tu, Zishu Wang, Bo Liu, Xiaohua Hu, Weixian Liu, Xiaofeng Li
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study. Cancer communications (London, England) 44 (8) (2024)
Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan, Weibo Wang, Jun Liang, Xianwen Zhang, Feng Ye, Ping Chen, Huaizhang Wang, Zhenyan Yu, Lu Yue, Yong Fang, Jianping Xiong, Jianwei Yang, Yiye Wan, Xianli Yin, Wenling Wang, Nong Xu, Xiaohong Wang, Zemin Xiao, Huafang Su, Ying Wang, Kangsheng Gu, Shuiping Tu, Zishu Wang, Bo Liu, Xiaohua Hu, Weixian Liu, Xiaofeng Li
SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study. Cancer communications (London, England) 44 (8) (2024)
Michael Schnekenburger, Anne Lorant, Sruthi Reddy Gajulapalli, Ridhika Rajora, Jin-Young Lee, Aloran Mazumder, Haeun Yang, Christo Christov, Hyoung Jin Kang, Bernard Pirotte, Marc F Diederich
Dual inhibition of sirtuins 1 and 2: reprogramming metabolic energy dynamics in chronic myeloid leukemia as an immunogenic anticancer strategy. Cancer communications (London, England) 44 (8) (2024)
Jian Xiao, Shuqing Cao, Jiawei Wang, Pengyu Li, Quan Cheng, Xinyi Zhou, Jiacheng Dong, Yuan Li, Xinyu Zhao, Zekuan Xu, Li Yang
Leptin-mediated suppression of lipoprotein lipase cleavage enhances lipid uptake and facilitates lymph node metastasis in gastric cancer. Cancer communications (London, England) 44 (8) (2024)
Rolf F Barth, Nilendu Gupta, Shinji Kawabata
Evaluation of sodium borocaptate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of cancer: an update and a guide for the future clinical evaluation of new boron delivery agents for NCT. Cancer communications (London, England) 44 (8) (2024)
Jian Xiao, Shuqing Cao, Jiawei Wang, Pengyu Li, Quan Cheng, Xinyi Zhou, Jiacheng Dong, Yuan Li, Xinyu Zhao, Zekuan Xu, Li Yang
Leptin-mediated suppression of lipoprotein lipase cleavage enhances lipid uptake and facilitates lymph node metastasis in gastric cancer. Cancer communications (London, England) 44 (8) (2024)
Michael Schnekenburger, Anne Lorant, Sruthi Reddy Gajulapalli, Ridhika Rajora, Jin-Young Lee, Aloran Mazumder, Haeun Yang, Christo Christov, Hyoung Jin Kang, Bernard Pirotte, Marc F Diederich
Dual inhibition of sirtuins 1 and 2: reprogramming metabolic energy dynamics in chronic myeloid leukemia as an immunogenic anticancer strategy. Cancer communications (London, England) 44 (8) (2024)
Anjali Chander, Jacopo Iacovacci, Aize Pellon, Rhadika Kataria, Anita Grigoriadis, John Maher, Cynthia Sears, Gilad Bachrach, Teresa Guerrero Urbano, Mary Lei, Imran Petkar, Anthony Kong, Tony Ng, Ester Orlandi, Nicola Alessandro Iacovelli, Loris De Cecco, Mara Serena Serafini, David Moyes, Tiziana Rancati, Miguel Reis Ferreira
Fusobacterium is toxic for head and neck squamous cell carcinoma and its presence may determine a better prognosis. Cancer communications (London, England) 44 (8) (2024)
Rolf F Barth, Gong Wu, Maria da Graca H Vicente, John C Grecula, Nilendu Gupta
Boron neutron capture therapy of cancer: where do we stand now? Cancer communications (London, England) 44 (8) (2024)
Anjali Chander, Jacopo Iacovacci, Aize Pellon, Rhadika Kataria, Anita Grigoriadis, John Maher, Cynthia Sears, Gilad Bachrach, Teresa Guerrero Urbano, Mary Lei, Imran Petkar, Anthony Kong, Tony Ng, Ester Orlandi, Nicola Alessandro Iacovelli, Loris De Cecco, Mara Serena Serafini, David Moyes, Tiziana Rancati, Miguel Reis Ferreira
Fusobacterium is toxic for head and neck squamous cell carcinoma and its presence may determine a better prognosis. Cancer communications (London, England) 44 (8) (2024)
Rolf F Barth, Nilendu Gupta, Shinji Kawabata
Evaluation of sodium borocaptate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of cancer: an update and a guide for the future clinical evaluation of new boron delivery agents for NCT. Cancer communications (London, England) 44 (8) (2024)
Sangyeop Hyun, Youngmin Han, Jae Yun Moon, Young-Ah Suh, Won-Gun Yun, Wooil Kwon, Jong-Eun Lee, Daeun Kim, Ja-Lok Ku, Jin-Young Jang, Deachan Park
Defining and tracing subtypes of patient-derived xenograft models in pancreatic ductal adenocarcinoma. Cancer communications (London, England) 44 (8) (2024)
Rolf F Barth, Nilendu Gupta, Shinji Kawabata
Evaluation of sodium borocaptate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of cancer: an update and a guide for the future clinical evaluation of new boron delivery agents for NCT. Cancer communications (London, England) 44 (8) (2024)